PANG · Pathogen and Graphene
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2016-01-01 → 2019-12-31
- EU contribution
- €580,500
- Participants
- 8
- Scheme
- MSCA-RISE
Lines connect the coordinator with its partners.
Results in brief
Pathogen and Graphene
While complications related to infectious diseases have significantly reduced due to the availability of a broad-range of antibiotics and a wide variety of antimicrobial agents, the number of death related to infections is only declining every year by only 1 %, with a forecast of 13 million deaths due to these cases in 2050. While the development of vaccinations and novel anti-bacterial drugs and treatments are at the forefront of research, excessive use of antibiotics and antimicrobial agents increased significantly the number of multi-drug resistant (MDR) bacteria and has resulted in a serious threat to public health. According to published data in 2011, 25.000 patients die annually in the EU as a result of infections caused by antibiotic-resistant bacteria, with two thirds of these deaths due to Gram-negative pathogens. The costs incurred by drug resistant infections amount to an estimated €1.5 billion annually, due to increases in healthcare expenditure costs. The situation is all the more serious as antimicrobials have become an essential tool for modern medicine and many surgical operations could not be performed without them. The inexorable rise in the incidence of antibiotic resistance in bacterial pathogens, coupled with the low rate of emergence of new clinically useful antibiotics, has refocused attention on finding alternatives to overcome antimicrobial resistance. Among the various approaches, the use of nanomaterials is currently considered a highly promising strategy due to their small size, which allows packaging multiple antimicrobial agents on the same nanoparticle making the development of resistance unlikely. This project is thus exploring the utility of novel graphene based nanocomposites and surfaces for the management and better understanding of microbial infections. The anti-microbical potential of the novel graphene based nanomaterials, the possibility of using such structures for the development of non-invasive therapies together with the understanding of the mechanism of action are the main focal points of the project entitled “PANG”, relating to Pathogen and Graphene. The objectives of PANG are: Objective I: Development of graphene-based antibacterial matrixes though chemical functionalization of these structures using antibacterial peptides and molecules (e.g. menthol and others) and test them for their toxicity and bactericidal potential (in particular against AMR strains) Objective II: Use of the novel architectures in form of suspensions and transdermal patches for the killing of pathogens via non invasive photothermal therapy taking advantage of the good photothermal properties of rGO Objective III: To get a deeper understanding of the effects of the novel structures on the immune system Objective IV: To develop prototypes of antibacterial graphene matrixes and antibacterial transdermal patches with the SMEs involved in the project The project impacts on science, society and economy in different ways. i) healthcare and well-being, ii) technology transfer and patenting, iii) formation of young researchers in truly interdisciplinary domain and iv) establishment of a network of knowledge. Impact on science & technology: The field of treatment of bacterial skin infections and others with such structures is still in its infancy. Among the various approaches to fight multi-drug resistant (MDR) bacteria, the use of graphene matrixes and interfaces is an important alternative. The possibility of a combination of nanostructures with light activation in a photodynamic and/or photothermal approach to fight against infectious diseases is still not a routine used in hospitals.
Data: CORDIS, © European Union
Project objective
Complications related to infectious diseases have significantly reduced, particularly in the developed countries, due to the availability and use of broad-range antibiotics and wide variety of antimicrobial agents. Excessive use of antibiotics and antimicrobial agents increased significantly the number of multi-drug resistant (MDR) bacteria. This has resulted in a serious threat to public health. The inexorable rise in the incidence of antibiotic resistance in bacterial pathogens, coupled with the low rate of emergence of new clinically useful antibiotics, has refocused attention on finding alternatives to overcome antimicrobial resistance. Novel strategies aiming to reduce the amount of antibiotics, but able to prevent and treat animal and human infections should be investigated, evidenced and approved. Among the various approaches, the use of graphene and its derivatives is currently considered a highly promising strategy to overcome microbial drug resistance.In line with this interest in graphene by the European Commission through the graphene ‘flagship’ initiatives, we respond in this consortium by exploring the utility of novel graphene based nanocomposites for the management and better understanding of microbial infections. The anti-microbical potential of the novel graphene based nanomaterials, the possibility of using such structures for the development of non-invase therapies together with the understanding of the mechanism of action will be the main focal points of the proposed project entitled “PANG”, relating to Pathogen and Graphene. We have gathered the essential elements, namely different academic institutions in Europe (France, Germany, and Sweden) and their associated countries (Ukraine) as well as two European companies (Graphenea-Spain and LSO Medical-France) and one company (RS RESEARCH) in one of the associated countries (Turkey). The proposed multidisciplinary project uniquely suits high-level interdisciplinary and cross-border training.
Original text from CORDIS.
Participants
- UNIVERSITE DE LILLE · LilleCoordinatorFrance
- GOETEBORGS UNIVERSITET · GoeteborgSweden
- GRAPHENEA SA · SAN SEBASTIAN GUIPUZCOASpain
- LSO MEDICAL · LOOSFrance
- LVIVSKYI NATIONALNYI MEDYCHNYI UNIVERSYTET IMENI DANYLA HALYTSKOHO · LvivUkraine
- RS ARASTIRMA EGITIM DANISMANLIK ILAC SANAYI TICARET ANONIM SIRKETI · IstanbulTürkiye
- RUHR-UNIVERSITAET BOCHUM · BochumGermany
- UNIVERSITATSKLINIKUM ERLANGEN · ErlangenGermany
Links
- View on CORDIS
- DOI: 10.3030/690836
- http://pang.univ-lille.fr
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5bae9a1eb&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5bb0d0b10&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c04af2e5&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c04afd0e&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c04afd10&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c04afd38&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c04afd5f&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c6eeeaa5&appId=PPGMS
- https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5ca62a60c&appId=PPGMS
Data: CORDIS, © European Union
